Dexrazoxane is a cytoprotective drug used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer. An antimitotic agent with immunosuppressive properties.
- Mechanism
- Curator reviewed
The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II.
- Primary indication
- For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin...Curator reviewed · 2 structured indications
- Formula / weight
- C11H16N4O4 · 268.2691 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1995 · European Union, 2016
- Also known as
- 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI) · 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI) · Dextrorazoxane
- Code names
- ADR-529 · ICRF-187 · NSC-169780
- Brand names
Resolves to
BMKDZUISNHGIBY-ZETCQYMHSA-NSMILESC[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Dexrazoxane, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account